Parameter
| Biomarker | SMAD4 mutant | Full name | SMAD family member 4 mutant | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognostic prediction and therapeutic targets | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Tissues (Next generation sequencing) | ||
| Pathobiological Mechanisms | SMAD4 is a key molecule in TGF-β signaling pathway. Mutation of Smad4 leads to loss of tumor suppressor function and promotes tumor invasion and metastasis | ||||
| Clinical Availability Status | Clinical research phase: used for prognostic evaluation, its absence is associated with poor prognosis | ||||
| Notes and Dynamics | Mutations are present in 30%-40% of patients with PDAC, and patients with mutated PDAC are more likely to have distant metastasis, which can be used as a prognostic stratification marker | ||||